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Introduction
Th  e human nervous system can be divided into two 
major components: the central nervous system (CNS) 
and the peripheral nervous system [1]. Th   e CNS consists 
of the brain and the spinal cord with the blood-brain 
barrier restricting the types of biomolecules that can 
reach these organs [2]. Th  e majority of neural tissue 
found in the CNS consists of two cell types: neuronal 
cells and glial cells. Neurons serve as the main infor-
mation transmitting unit of the nervous system, which 
can be classiﬁ   ed as either sensory, allowing them to 
detect stimuli from the environment, or motor, respon-
sible for the generation of movement through signaling 
with muscle tissue [3]. Glial cells encompass a number of 
diﬀ  erent types of support cells, including astrocytes and 
oligodendrocytes found in the CNS [4,5]. Th   is review will 
discuss the use of embryonic stem (ES) cell therapy as a 
method of treating injuries and diseases that inﬂ  ict 
damage to the CNS. Th  ese studies are particularly 
relevant now as the ﬁ  rst human ES-cell-derived therapy 
is currently being evaluated in clinical trials as a potential 
method for treating spinal cord injury (SCI) [6].
ES cells possess two hallmark characteristics: the ability 
to self-renew and pluripotency [7]. Th  e pluripotent 
nature of ES cells allows them to generate the cells found 
in neural tissue, including neurons and glia. As a result, 
ES-cell-based regeneration strategies have been investi-
gated for a number of diseases as well as for repairing 
mechanically damaged nerve tissue. While many other 
types of stem cells have been evaluated for their potential 
to promote neural repair, this review will focus speciﬁ  -
cally on the attempts made with ES cells as this work will 
be most applicable to developing therapies using induced 
pluripotent stem (iPS) cells. First generated in 2006, iPS 
cells are produced from adult somatic cells, such as skin 
cells, by inducing speciﬁ   c factors that restore pluri-
potency [8-10] (Figure 1). Th   e recent generation of these 
cell lines serves as an exciting alternative to traditional ES 
cell lines and recent research using iPS cells will also be 
critically examined in terms of the future of stem-cell-
based therapies for repairing neural tissue.
Many of the studies detailed in this review use mouse 
ES cells as a model system for studying cell behavior with 
the goal of translating this knowledge to human ES cells. 
While this approach does have merit, it is important to 
note some of the diﬀ  erences between mouse and human 
ES cell lines. One of the major diﬀ  erences is that mouse 
ES cells can be maintained in the presence of leukemia 
inhibitory factor (LIF) on gelatin substrates in a relatively 
cost eﬀ  ective manner while human ES cells are cultured 
either on a feeder layer of cells or on a Matrigel surface in 
the presence of deﬁ  ned media [11]. Mouse and human ES 
cells diﬀ  er in protein expression patterns, including the 
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markers that indicate pluripotency [12]. For example, 
undiﬀ   erentiated mouse ES cells express stage-speciﬁ  c 
embryonic antigen (SSEA)-1 while undiﬀ  erentiated human 
ES cells express the SSEA-3 and SSEA-4 markers [13]. 
Th  us, the information gained in mouse ES cell studies 
does not always directly translate to human ES cell lines 
due to these intrinsic diﬀ  erences.
Both human ES and iPS cells exhibit high variability 
between diﬀ  erent cell lines as illustrated by a recent study 
published in Cell that mapped the genome-wide DNA 
methylation patterns and gene expression for 20 ES and 
12 iPS cell lines [14]. Th   ey used the information obtained 
from the ES cell lines as a reference to evaluate the 
expression patterns of the iPS cell lines to see if they fell 
within an acceptable range of ‘stemness’. Another study 
used transcriptional proﬁ  ling analysis to show that the 
iPS cell lines have residual gene expression from the 
donor cells after reprogramming, with certain donor cells 
being reprogrammed more eﬃ   ciently [15]. Both of these 
studies illustrate the need for deﬁ  ned standards to use for 
evaluating newly derived ES and iPS cell lines to deter-
mine their suitability for clinical applications.
Embryonic stem-cell-based therapies for neural 
tissue replacement
Many diﬀ  erent studies have used ES cells to generate 
replacement neural tissue for a variety of diseases and 
disorders (Table  1). One of the major considerations 
when working with ES cells is how to induce them to 
diﬀ  erentiate into the speciﬁ  c neural phenotypes neces-
sary for treating the particular application. Regeneration-
promoting strategies can include directly deriving the 
desired cell type to be replaced or generating supporting 
glial cells that secrete factors to help restore lost 
functionality. In terms of diﬀ  erentiation protocols, the 
most desirable methods would produce a highly puriﬁ  ed 
population of speciﬁ  c cellular phenotypes for trans  plan-
tation as any undiﬀ  er  en  tiated ES cell clusters remaining 
can proliferate in an uncontrolled fashion, leading to 
teratoma formation [16]. To avoid teratoma formation, 
many diﬀ   erent methods have been investigated to 
Figure 1. The use of pluripotent stem cells for engineering neural tissue. The diagram compares the derivation of embryonic stem cell lines 
from the inner cell mass of the blastocyst and how induced pluripotent stem cells are derived from somatic cells by induction of the Yamanaka 
factors. These pluripotent stem cells can then be directed to diff  erentiate into the three main cell types found in the central nervous system 
(neurons, oligodendrocytes, and astrocytes).
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undiﬀ   erentiated ES cells [17]. Th  ese methods include 
using cell sorting to isolate a speciﬁ  c progenitor popu-
lation and performing extensive diﬀ  eren  tiation protocols 
to ensure only mature cells are transplanted. Other ways 
to eliminate the undiﬀ  eren  tia  ted ES cell populations after 
transplantation include the development of an ES cell 
line modiﬁ  ed with an inducible suicide gene expressed 
under a promoter element used to maintain ‘stemness’ 
and the use of targeted anti-human ES cell antibodies 
that induce apotosis of undiﬀ  erentiated ES cells [18-20].
While speciﬁ  c protocols for directing stem cell diﬀ  er-
entiation into neural lineages will not be reviewed in 
depth here, several reviews on the subject describe these 
processes in more detail [21,22]. When developing ES-
cell-based treatments for neural diseases and disorders, it 
is important to consider what speciﬁ  c cell populations 
could potentially restore lost function. For certain neuro-
degenerative disorders that aﬀ  ect speciﬁ  c neuronal popu-
la  tions, the goal is to transplant a highly diﬀ  erentiated 
mature population of neurons to replace the lost cells. 
For promoting recovery after traumatic CNS injury, a 
variety of ES-cell-based therapies have been explored as 
neural progenitors could potentially secrete regeneration-
promoting factors while the transplantation of ES-cell-
derived neurons and oligodendrocytes to restore the lost 
mature cellular populations has also been studied. Th  e 
method of transplanting the cells in the desired location 
in the CNS should also be carefully evaluated to ensure 
cell viability and prevent unwanted diﬀ  erentiation. Other 
relevant issues relating to ES-cell-based therapies include 
the potential of the transplanted cells to induce an 
immune response. Th  ese issues will be discussed along 
with the relevant studies for each of the following 
diseases and disorders.
Traumatic brain injury
It is estimated that 3.2 million people in the United States 
currently suﬀ  er from reduced function after hospitali-
zation as a result of traumatic brain injury (TBI) [23]. Th  e 
impact and resulting lesion from TBI often results in 
cognitive, sensory, motor, and emotional impairments. 
Several studies have investigated the use of ES-cell-
derived therapies, speciﬁ   cally the transplantation of 
neural progenitors and undiﬀ  erentiated ES cells, as a way 
of treating TBI with the hope of alleviating the afore-
mentioned symptoms as these cells could secrete factors 
that would induce regeneration. In one of the ﬁ  rst studies 
to investigate such a strategy, neural progenitors pro-
duced by treating mouse ES cells with retinoic acid were 
transplanted into the lesion site one week after 
administration of a cortical impact injury [24]. Th  ey 
found that these cells were able to prevent the formation 
of necrotic cavities that would normally occur after 
injury and were able to improve the sensorimotor func-
tion. Another group showed transplanted mouse ES cells 
migrated to the injury sites consisting of lesions induced 
by ﬂ  uid injection in the mouse brain, suggesting that the 
damaged brain tissue secreted factors to induce ES cell 
migration [25]. In a similar study, the ability of undiﬀ  er-
entiated mouse ES cells to promote recovery after TBI 
was evaluated [26]. Th   e animals that received the ES cells 
performed better on the Rotorod test, measuring the 
animal’s ability to stay on a moving rod, and had better 
Neuroscores, reﬂ  ecting an improvement in their neuro-
motor function. However, they observed tumor forma-
tion in two of the ten animals receiving the cells, 
illustrating a limitation of using undiﬀ  erentiated ES cells 
as a therapy. In a follow-up study, they reported that the 
inﬂ  ammatory response associated with TBI impaired ES 
cell survival and integration after implantation into 
injured rat brain [27]. Th   ese studies illustrate the poten-
tial of ES cell therapies for the treatment of TBI, but 
much work remains before such therapies will be suitable 
for evaluation in clinical trials.
Parkinson’s disease
Th  e loss of dopaminergic neurons located in the sub-
stantia nigra is one of the major hallmarks of Parkinson’s 
disease (PD) [28]. Th  ese neurons secrete dopamine, 
which regulates cortical and thalamic activity. Loss of 
these dopamine neurons in the substantia nigra results in 
motor dysfunction, including tremor, rigidity, and brady-
kinesia, as well as non-motor symptoms, including 
anxiety and depression. Th  e current treatment for PD 
consists of the drug levodopa, often referred to as L-dopa, 
Table 1. The use of embryonic stem and induced 
pluripotent stem cell derived therapies for neural tissue 
engineering applications
Disease/disorder Cell  lines  References
Traumatic brain injury  Mouse embryonic stem cells  [24-27]
Parkinson’s disease  Mouse embryonic stem cells  [34,35,40]
  Human embryonic stem cells  [36-39,41]
  Mouse induced pluripotent cells  [88]
  
Huntington’s disease  Human embryonic stem cells  [47-49]
  
Alzheimer’s disease  Mouse embryonic stem cells  [51,52]
  
Spinal cord injury  Mouse embryonic stem cells  [54-58,60,62,
     64, 68,77-79,81]
  Human embryonic stem cells  [65,67,69,70,
   72,74,82]
  Mouse induced pluripotent cells  [87,88]
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brain barrier, where it is then metabolized into dopamine 
[29]. However, long-term use of levodopa leads to more 
motor function dysregulation [30]. Additionally, the 
transplantation of fetal tissue as a method of replacing 
the lost dopamine neurons has also been investigated, 
but the most recent clinical trials did not show any 
beneﬁ  t to receiving this treatment [31-33]. Th  e goal of 
ES-cell-based therapies for PD is to generate a highly 
deﬁ   ned, dopaminergic neuron population suitable for 
transplantation into the substantia nigra.
Many groups have investigated the use of ES-cell-
derived dopaminergic neurons for their potential to treat 
PD as an alternative to the current standard of care. One 
group implanted undiﬀ  erentiated mouse ES cells directly 
into the mid-brain, where the cells diﬀ  erentiated  into 
functional dopaminergic neurons and promoted func-
tional recovery in a rat model of PD induced by injections 
of 6-hydroxydopamine [34]. Another study developed an 
extensive ﬁ  ve step protocol for generating dopaminergic 
neurons from mouse ES cells and showed that trans-
plantation of these cells improved function in the same 
PD rat model [35]. Similar studies were also performed 
using human ES-cell-derived dopaminergic neurons and 
showed that transplantation of these cells into a rat 
model of PD produced similar improvements in function 
[36-39]. Other groups have shown that co-cultures of ES 
cells with astrocytes and stromal cells induces diﬀ  eren-
tiation into dopaminergic neurons [37,40,41]. Finally, a 
recent study developed an eﬃ     cient protocol for large 
scale production of dopaminergic neurons from human 
ES cells that reduces the potential for tumor formation, 
bringing this therapy closer to standards required for 
clinical testing [39].
Huntington’s disease
Huntington’s disease (HD) is a rare, inherited neuro-
degenerative disorder characterized by a loss of medium 
spiny projection neurons in the striatum [42]. Symptoms 
include loss of muscular coordination along with 
progressive cognitive decline. Many clinical studies have 
investigated the transplantation of fetal-derived tissue 
into the brain as a potential treatment for HD [43-46] 
and ES cells provide an alternative to the use of such 
tissues by providing an alternative way to replace the lost 
neuronal population.
One study induced human ES cells to diﬀ  erentiate into 
neural progenitors and then transplanted these cells into 
a rat model of HD induced using quinolinic acid [47]. Th  e 
animals receiving the treatment performed better on an 
apomorphine-induced rotation test compared to sham 
treated animals and no tumor formation was observed. 
While they did observe neuronal diﬀ  erentiation of the 
transplanted progenitors, they did not investigate the 
mechanism behind the observed recovery to determine if 
it was due to the secretion of factors that preserved the 
existing cells or if the transplanted cells were contributing 
to the functional recovery. A second study utilized a 
three step protocol to induce human ES cells to diﬀ  er-
entiate speciﬁ  cally into striatal spiny neurons for trans-
plantation [48]. While the initial results were promising, 
after 13 weeks, the grafts overgrew the implantation site, 
leading to deleterious side eﬀ  ects. However, these grafts 
did not contain undiﬀ  erentiated ES cells, but the regions 
of overgrowth did contain nestin-positive neural 
progenitor cells. A diﬀ  erent study showed that treatment 
of neural progenitors derived from human ES cells with 
the protein Noggin enhanced neuronal diﬀ  erentiation 
post-implantation in a rat model of HD [49]. Th  ese 
studies demonstrate the viability of using ES-cell-derived 
therapies as a way to replace the lost neuronal popula-
tions due to HD. However, the issue of graft overgrowth 
as well as determining how these transplanted cells 
contribute to function recovery will have to be addressed 
and characterized before these therapies can be trans-
lated to the clinic.
Alzheimer’s disease
Similar to HD, Alzheimer’s disease (AD) is another 
neuro  degenerative disease that tends to aﬀ  ect  people 
over the age of 65 years. Th  e clinical symptoms of AD 
include progressive cognition deterioration due to the 
loss of cholinergic neurons [50]. In terms of histology, 
AD is associated with the appearance of amyeliod plaques 
and neuroﬁ   brillary tangles in the brain. Many groups 
have investigated the use of ES-cell-derived therapies as a 
means of treating AD in pre-clinical models by diﬀ  er-
entiating ES cells into cholinergic neurons as this cell 
population is one the most aﬀ  ected by AD.
One group derived neurospheres from mouse ES cells 
and transplanted the resulting cells into a mouse model 
of AD [51]. Th   ese cells diﬀ  erentiated into choline acteyl-
transferase-positive neurons and reduced memory 
deteri  oration compared to control mice that received 
undiﬀ  erentiated ES cells. Th   e control mice receiving the 
undiﬀ  erentiated ES cell transplants also showed tumor 
formation and signiﬁ  cant memory deterioration. Another 
study took a similar approach to diﬀ  erentiating mouse ES 
cells and also examined the eﬀ  ect of adding the growth 
factor sonic hedgehog (Shh) during the neurosphere 
formation step. Th   ey observed that the diﬀ  erentiation of 
neural progenitors into cholinergic neurons was en-
hanced by priming the neurospheres with Shh and the 
treated animals that received these cells showed a signiﬁ  -
cant improvement in memory as indicated by perfor-
mance in a water maze test [52]. Th  ese studies provide 
preliminary evidence for an ES-cell-based therapy for 
AD, but such results would need to be repeated with 
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viability of such a strategy.
Spinal cord injury
Th   e complex arrangement of neurons, oligodendrocytes, 
and astrocytes allow the spinal cord to coordinate move-
ment and sensation between the brain and the limbs and 
disruption of this structure due to mechanical injury can 
result in paralysis [53]. Th   e extent of paralysis depends on 
the degree of trauma and the location of the injury in the 
spinal cord. Th  e initial mechanical injury triggers a 
secondary cascade of events and damage from both of 
these processes must be addressed when designing a 
suitable therapeutic repair strategy. ES-cell-based thera-
pies for the treatment of SCI have focused on generating 
both neurons and oligodendrocytes to promote recovery 
after injury.
Th  e McDonald group [54] transplanted retinoic-acid-
treated ES cells into a rat model of SCI and these cells 
were able to survive and diﬀ   erentiate into neurons, 
oligodendrocytes, and astrocytes while promoting recovery 
as indicated by regained hind limb function. Other 
groups using similar approaches observed improve  ments 
in motor and sensory function after transplantation of 
pre-diﬀ  erentiated mouse ES cells [55-57]. Another group 
showed that transplantation of bone marrow stromal 
cells along with retinoic-acid-treated mouse ES cells 
prevented tumor formation in a rat model of SCI [58]. 
Other studies have used genetically modiﬁ  ed ES cell lines 
to improve cell survival and diﬀ  erentiation after trans-
plantation, but the use of virus-mediated transfection 
methods limit the feasibility of such approaches [59-62].
More recent work has focused on the production of 
speciﬁ  c cellular populations from ES cells for treatment 
of SCI. Many groups have chosen to diﬀ  erentiate ES cells 
into motor neurons as a therapeutic strategy. One 
approach involved inducing mouse ES cells to diﬀ  eren-
tiate into motor neurons using a combination of retinoic 
acid and Shh and transplanted these cells into a virus-
mediated rat model of SCI, with approximately 25% of 
these cells surviving one month after transplantation 
[63]. Another group transplanted ES-cell-derived motor 
neurons along with olfactory ensheathing cells into a rat 
model of SCI and observed partial functional recovery 
[64]. Th   e Keirstead group has shown that motor neurons 
derived from human ES cells can also promote functional 
recovery after SCI in a rat model [65]. Th   is strategy also 
holds potential for the treatment of amyotrophic lateral 
sclerosis, a neurodegenerative disease characterized by 
the loss of motor neurons [66].
Th  e other major therapeutic strategy has involved 
diﬀ  er  entiating ES cells into oligodendrocytes for treating 
SCI [67-74]. One of the most promising approaches to 
treatment of SCI involves diﬀ  erentiating human ES cells 
into oligodendrocyte precursors using an extensive 
42-day diﬀ  erentiation protocol [71] and then transplant-
ing these cells into the site of SCI [70,72-74]. Th  is  therapy 
showed promising results in pre-clinical trials as these 
oligodendrocyte precursors diﬀ   erentiated into mature 
oligodendrocytes, promoting functional recovery in two 
distinct models of SCI [72,74]. Th   is therapy has become 
the ﬁ  rst human ES-cell-derived therapy to be evaluated 
in clinical trials [6], with the ﬁ  rst patient having already 
been enrolled [75]. Th  e Keirstead group [65] has also 
begun researching the eﬀ   ects of transplanting motor 
neuron progenitors into the injured rat spinal cord with 
some promising results.
Several groups have used tissue engineering approaches 
that combine biomaterial scaﬀ  olds with ES cells for the 
treatment of SCI. Th   e Sakiyama-Elbert group [76-81] has 
used a ﬁ  brin-based scaﬀ  old to deliver growth factors that 
promote ES cells to diﬀ  erentiate into neurons and oligo-
dendrocytes and this approach has been shown to 
enhance functional recovery in a rat model of SCI. Th  e 
Baharvand group [82] has investigated the transplan-
tation of neural progenitors derived from human ES cells 
inside of collagen scaﬀ  olds for the treatment of SCI and 
this approach also resulted in an increase in locomotor 
function post-transplantation. Another group developed 
electrospun poly (ε)-caprolactone scaﬀ  olds, which support 
mouse ES cell culture and promoted diﬀ  erentiation into 
nestin-positive neural progenitors in an in vitro setting 
[83]. Many other biomaterials have been investigated for 
the treatment of SCI, but not in combination with stem 
cells [84,85].
Reprogramming somatic cells and the potential for 
engineering neural tissue
As mentioned in the Introduction, the recent develop-
ment of iPS cells provides an exciting alternative to the 
use of ES cells. Th  ese cells are generated from somatic 
cells, such as ﬁ  broblasts, by upregulating the expression 
of speciﬁ   c genes (Oct3/4,  Sox2, c-Myc, and Klf4) that 
restore pluripotency [9,10]. Unlike traditional ES cell 
lines, the use of iPS cells allows for generation of pluri-
potent cell lines without the use of embryos as well as for 
the production of patient-speciﬁ  c iPS cell lines, which 
should reduce the risk of rejection after transplantation.
Several studies have investigated iPS cells and their 
potential for diﬀ  erentiating into neural phenotypes. A 
recent study demonstrated that neural diﬀ  erentiation in 
human iPS cells uses the same transcription networks as 
traditional human ES cell lines [86]. Th   ey also observed 
lower diﬀ  erentiation eﬃ   ciency and increased variability 
compared to ES cells, suggesting that more eﬃ   cient 
diﬀ  er  entiation protocols may need to be developed to 
fully utilize the potential of iPS cells (Figure 2). In work 
also done by the Yamanaka lab [87], 36 mouse iPS cell 
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generat  ing neural phenotypes after secondary neuro-
sphere formation as well as their potential safety for 
transplantation as indicated by teratoma formation in an 
in vivo setting. After an induction period using retinoic 
acid, these cell lines demonstrated the ability to diﬀ  er  en-
tiate into the three cell types found in the CNS (neurons, 
oligodendrocytes, and astrocytes) and certain iPS cell 
lines did not form teratomas after implantation, leading 
them to be classiﬁ  ed as a ‘safe’ cell line. In a follow-up 
study, neural progenitor cells derived from ‘safe’ iPS cell 
lines were implanted into both uninjured spinal cord 
tissue and a pre-clinical model of SCI in mice [88]. In the 
uninjured mice, the cells diﬀ  erentiated into neurons and 
glia, while in the injured animals, these cells diﬀ  erentiated 
into mature oligodendrocytes and promoted functional 
recovery in the hind limbs of mice. Other work has 
derived neurons from iPS cells, which were shown to 
promote functional recovery in a rat model of PD [89]. 
Th  ese studies indicate the ability of iPS cells to diﬀ  er-
entiate into neural phenotypes, illustrating their potential 
as an alternative to the use of traditional ES cell lines. Th  e 
generation of ‘safe’, non-teratoma-forming cell lines 
serves as an added potential beneﬁ  t of using iPS cells.
An alternative approach to diﬀ  erentiating pluripotent 
stem cells is to directly convert one mature cell type into 
the desired cell type by manipulating cell signaling 
pathways. Th   e Wernig group [90] recently demonstrated 
that mouse embryonic ﬁ   broblasts can be directly 
converted to neurons if the appropriate factors were 
expressed, oﬀ   ering a potential method of engineering 
neural tissue without the use of pluripotent stem cells. 
Much work remains to be done to determine the 
feasibility of such an approach for clinical applications.
Conclusion
Overall, a large body of work exists showing the potential 
of using pluripotent stem cells to produce replacement 
Figure 2. Human induced pluripotent stem cells and human embryonic stem cells follow the same temporal course of neural 
diff  erentiation. (a) Phase contrast images show that embryonic stem (ES) cells and induced pluripotent stem (iPS) cells grew as individual 
colonies, diff  erentiated to columnar epithelial cells at days 8 to 10, and formed neural tube-like rosettes at day 15. (b) Both iPS cells and ES cells 
were positive for OCT4 at day 0, for PAX6 but not SOX1 at days 8 to 10, and for both PAX6 and SOX1 at day 15. (c) Fluorescence activated cell 
sorting analysis indicates that diff  erentiating cells from H9 human embryonic stem cells (hESCs), iPS(IMR90)-1 and -4, iPS-M4-10, iPS-DF6-9–12, 
and iPS109 began to generate PAX6-expressing cells at days 6 to 8, and reached a plateau at day 14 but with diff  erent effi   ciency. (d,e) By 12 weeks 
in culture, many MAP2+ neurons also expressed synapsin (SYN); (e) higher magnifi  cation indicates a punctuate staining pattern on the cell 
bodies and neurites. (f) Glial fi  brillary acidic protein (GFAP)-positive astrocytes were present in diff  erentiated cultures at 12 weeks. (g) O4-positive 
oligodendrocytes were observed in cultures after 16 weeks. O4, oligodendrocyte marker referring to oligodendrocyte clone number 4. Scale bars: 
50 μm. Reprinted from [86] with permission from the National Academy of Sciences.
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current evaluation of oligodendrocytes derived from 
human ES cells shows the promise of this technology for 
the treatment of SCI and other neurological disorders 
and diseases while the generation of iPS cell lines now 
allows for generation of patient-speciﬁ   c neural tissue 
derived from pluripotent stem cells. Additionally, the 
recent work from the Wernig group showing the direct 
conversion of somatic cells into neurons provides an 
intriguing alternative to diﬀ  erentiating pluripotent stem 
cells as a means of replacing lost neural tissue.
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